Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK202 in Combination With Different Drugs in NSCLC
NCT07603791Phase 2Not yet recruiting
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, randomised, open-label trial of ALK202 in non-small cell lung cancer (NSCLC) (3 cohorts), sponsored by Shanghai Allink Biotherapeutics Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events at 12 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ALK202
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07603791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07603791.